Vanguard Group Inc. Sells 466,470 Shares of Hologic, Inc. (NASDAQ:HOLX)

Vanguard Group Inc. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,679,701 shares of the medical equipment provider’s stock after selling 466,470 shares during the period. Vanguard Group Inc. owned 11.79% of Hologic worth $1,977,715,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Hologic in the fourth quarter worth about $27,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 227 shares in the last quarter. Allworth Financial LP lifted its position in shares of Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 179 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 468 shares in the last quarter. Finally, BKM Wealth Management LLC purchased a new stake in shares of Hologic in the fourth quarter worth about $86,000. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price objective for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Argus upped their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Finally, Evercore ISI upped their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Hologic Trading Up 0.1 %

Shares of NASDAQ HOLX opened at $71.47 on Wednesday. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The company has a market cap of $16.68 billion, a price-to-earnings ratio of 36.46, a PEG ratio of 2.39 and a beta of 1.00. The business’s 50 day moving average price is $75.05 and its 200-day moving average price is $74.14. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the firm earned $1.06 earnings per share. Hologic’s revenue was down .8% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.